All In Biotech

Drug Trial Radar · NCT05950945

Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer

A Phase 3b, Multicenter, Global, Interventional, Open-label Study of Trastuzumab Deruxtecan (T-DXd), an Anti-HER2-Antibody Drug Conjugate (ADC), in Subjects Who Have Unresectable and/or Metastatic HER2-low or HER2 Immunohistochemistry (IHC) 0 Breast Cancer (DESTINY-Breast15)

Last checked: Nov 20, 2026Latest source record: Jun 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Dec 30, 2023

Primary completion

Oct 1, 2027

Study completion Oct 1, 2027

Sponsor

Lead sponsor
Daiichi SankyoDaiichi Sankyo (DSNKY)
Sponsor type
Industry
Collaborators
AstraZeneca
First posted
Jul 18, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study will evaluate the safety and efficacy of trastuzumab deruxtecan (T-DXd) in participants with human epidermal growth factor receptor 2 (HER2)-low or HER2 immunohistochemistry (IHC) 0 (who are both hormone receptor \[HR\]-negative and HR-positive) unresectable and/or metastatic breast cancer.

Conditions

  • Breast Cancer

Interventions

  • Trastuzumab DeruxtecanDrug

    Intravenous administration, 5.4 mg/kg on Day 1 of each 21-day cycle until radiographic disease progression as assessed by the investigator, unacceptable toxicity, other discontinuation criteria are met, or 2 years after first dose of study drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time From the Start of T-DXd to Initiation of Subsequent Anticancer Treatment (TTNT)Time frame: Until subsequent therapy or death, assessed up to 24 months

Locations

88 sites in 10 countries. Site status is shown where the registry gives one.

  • Mount Sinai Medical Center

    Miami Beach, Florida · Terminated

  • USF College of Medicine

    Tampa, Florida · Withdrawn

  • Dana-Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Beth Israel Lahey Health

    Burlington, Massachusetts · Withdrawn

  • Overlook Medical Center

    Summit, New Jersey · Recruiting

  • GenesisCare St Andrews Hospital

    Adelaide, Australia · Terminated

  • Fiona Stanley Hospital

    Murdoch, Australia · Withdrawn

  • Mater Hospital Sydney

    North Sydney, New South Wales, Australia · Terminated

  • Monash Medical Centre Moorabbin

    East Bentleigh, Victoria, Australia · Terminated

  • Institut Jules Bordet

    Anderlecht, Belgium · Recruiting

  • GZA Ziekenhuizen

    Antwerp, Belgium · Withdrawn

  • Universitair Ziekenhuis Brussel

    Brussels, Belgium · Withdrawn

  • Cliniques Universitaires Saint-Luc

    Brussels, Belgium · Withdrawn

  • UZ Leuven

    Leuven, Belgium · Withdrawn

  • Centre Hospitalier Universitaire de Liege Sart-Tilman

    Liège, Belgium · Withdrawn

  • GZA Ziekenhuizen

    Wilrijk, Belgium · Recruiting

  • Centro de Oncologia - Unidade Brasília - Hospital Sírio Libanês

    Brasília, Brazil · Recruiting

  • CIONC-Centro Integrado de Oncologia de Curitiba

    Curitiba, Brazil · Recruiting

  • Hospital Erasto Gaertner - Liga Paranaense de Combate ao Câncer

    Curitiba, Brazil · Recruiting

  • CEPON - Centro de Pesquisas Oncológicas de Santa Catarina

    Florianópolis, Brazil · Recruiting

  • Oncosite - Centro de Pesquisa Clinica e Oncologia

    Ijuí, Brazil · Recruiting

  • Fundação Doutor Amaral Carvalho

    Jaú, Brazil · Recruiting

  • Instituto de Cancer de Londrina

    Londrina, Brazil · Recruiting

  • Hospital das Clínicas FMRP-USP

    Riberão Preto, Brazil · Recruiting

  • Hospital Nossa Senhora da Conceicao

    Rio Grande, Brazil · Recruiting

  • Ensino e Terapia de Inovação Clínica AMO-ETICA

    Salvador, Brazil · Recruiting

  • Catarina Pesquisa Clinica

    Santa Catarina, Brazil · Recruiting

  • CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia

    Santo André, Brazil · Recruiting

  • Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto

    São José do Rio Preto, Brazil · Recruiting

  • ICESP - Instituto do Câncer do Estado de São Paulo Octavio Frias de Oliveira

    São Paulo, Brazil · Recruiting

  • Clínica de Pesquisas e Centro de Estudos em Oncologia Ginecológica e Mamária Ltda

    São Paulo, Brazil · Recruiting

  • Beijing Hospital

    Beijing, China · Recruiting

  • 307 Hospital of PLA

    Beijing, China · Recruiting

  • Fujian Cancer Hospital

    Fujian, China · Recruiting

  • Sun Yat sen University Cancer Center

    Guangzhou, China · Recruiting

  • Zhejiang Cancer Hospital

    Hangzhou, China · Recruiting

  • Anhui Provincial Cancer Hospital

    Hefei, China · Recruiting

  • Shandong Cancer Hospital

    Jinan, China · Recruiting

  • Yunnan Cancer Hospital

    Kunming, China · Withdrawn

  • Nanchang People's Hospital

    Nanchang, China · Recruiting

Showing 40 of 88 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.